Company / Cost of Revenue
Nuo Therapeutics, Inc. Cost of Revenue History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.1M
FY2017
5-year range
$729.0K / $8.5M
FY2013-FY2017
Trend
+49.7%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 7 years, ranging from $729,050 in FY2016 to $8M in FY2013.
Based on SEC 10-K filings.
$1M in FY2017 with a 5-year CAGR of -22.5%.
Improved from $8M to $1M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -45.6%
- 5-Year CAGR
- -22.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -22.5%, indicating a declining trend.
- In FY2017, cost of revenue increased 49.7% year-over-year.
- Peak cost of revenue was recorded in FY2013.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -45.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $1.1M | +49.7% |
| FY2016 | $729.0K | -90.8% |
| FY2015 | $8.0M | +17.7% |
| FY2014 | $6.8M | -19.9% |
| FY2013 | $8.5M | +115.9% |
| FY2012 | $3.9M | +43.5% |
| FY2011 | $2.7M | - |
As of FY2017 · SEC 10-K · Updated Jun 29, 2026